Analytical Data
-
Gene name
IL-13Rα1
-
简介
The IL-13R alpha 1 protein forms a receptor for interleukin-13 when it complexes with IL4RA, activating pathways in allergy response and bronchial asthma. It exhibits ubiquitous expression, including in large intestine adult, colon adult, and 27 other tissues. IL-13R alpha 1 Protein, Mouse (HEK293, His) is the recombinant mouse-derived IL-13R alpha 1 protein, expressed by HEK293 , with C-6*His labeled tag.
- Application
-
Biological Activity
Measured by its ability to inhibit IL-13-dependent proliferation of TF-1 human erythroleukemic cells. The ED50 for this effect is 0.690 µg/mL in the presence of 4 ng/mL rmIL-13, corresponding to a specific activity is 1.449×103 units/mg. Measured by its ability to inhibit IL-13-dependent proliferation of TF‑1 human erythroleukemic cells. The ED50 for this effect is 0.690 µg/mL in the presence of 4 ng/mL rmIL-13. corresponding to a specific activity is 1.449×103 units/mg.
-
Alternative Names
IL13RA1; CD213A1; IL-13Ra; NR4; RP13-128O4.2; IL13Rα1
-
Species
Mouse
-
Source
HEK293
-
Tag
C-6*His
-
Purity
Greater than 95% as determined by reducing SDS-PAGE. as determined by SDS-PAGE.
-
Uniprot
O09030
-
Expression Region
A26-T340
-
AA Sequence
ATEVQPPVTNLSVSVENLCTIIWTWSPPEGASPNCTLRYFSHFDDQQDKKIAPETHRKEELPLDEKICLQVGSQCSANESEKPSPLVKKCISPPEGDPESAVTELKCIWHNLSYMKCSWLPGRNTSPDTHYTLYYWYSSLEKSRQCENIYREGQHIACSFKLTKVEPSFEHQNVQIMVKDNAGKIRPSCKIVSLTSYVKPDPPHIKHLLLKNGALLVQWKNPQNFRSRCLTYEVEVNNTQTDRHNILEVEEDKCQNSESDRNMEGTSCFQLPGVLADAVYTVRVRVKTNKLCFDDNKLWSDWSEAQSIGKEQNST
-
Protein Length
Partial
-
Molecular Weight
47-64 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Interleukin-13 receptor subunit alpha-1 (IL-13Rα1) is a key player in the signaling pathways of interleukin-13 (IL-13), a cytokine involved in various biological processes, including immune response and inflammation. Abnormal IL-13 signaling is implicated in a range of diseases, particularly allergic conditions such as asthma, as well as fibrosis in organs like the lungs and liver. The IL-13Rα1 protein is known to form a functional receptor complex with IL-4Rα, enabling the modulation of cellular responses in immune cells. Due to its pivotal role in mediating the effects of IL-13, IL-13Rα1 has emerged as a potential therapeutic target for treating asthma and other IL-13 related disorders. Researchers have focused on developing recombinant IL-13Rα1 proteins to study their structure, function, and interactions with IL-13 and IL-4. These studies are essential for understanding the molecular mechanisms underlying IL-13 signaling and the development of new therapeutic strategies. Additionally, recombinant IL-13Rα1 could serve as a valuable tool in the development of novel antibodies or inhibitors, potentially leading to improved treatments for inflammatory diseases. Overall, the investigation of IL-13Rα1 recombinant proteins holds significant promise for advancing our understanding of IL-13-related pathologies and developing innovative treatment options.
